

# CTAD Alzheimer 2019

Clinical Trials on Alzheimer's Disease

**EARLY BIRD  
REGISTRATION  
DEADLINE**  
**SEPTEMBER 17**

**PRELIMINARY PROGRAM**

**LATE BREAKING CALL FOR ABSTRACTS**

**September 3-17, 2019**

**SAN DIEGO, California**

Hilton Bayfront San Diego

**December 4-7, 2019**

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11  
Monte Carlo '12 / San Diego '13 / Philadelphia '14  
Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)



MONTPELLIER and TOULOUSE EADC Centers  
European Alzheimer's Disease Consortium

Keck School of Medicine of USC  
**Alzheimer's Therapeutic Research Institute**



# SUMMARY

Organizing & Scientific Committees	3
Preliminary program	4
Wednesday, December 4	4
Thursday, December 5	4
Friday, December 6	6
Saturday, December 7	9
Registration / Accommodations	11

CTAD 2019  
San Diego



## CTAD Organizing Committee

**Jacques Touchon MD, PhD**  
University  
Hospital of Montpellier  
France

**Paul Aisen MD**  
Alzheimer's  
Therapeutic Research Institute (ATRI)  
University of Southern California (USC),  
San Diego, USA

**Bruno Vellas MD, PhD**  
University  
Hospital of Toulouse  
France

**Mike Weiner MD**  
University of California  
San Francisco (UCSF)  
USA

## CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco); Paul AISEN (San Diego); Kaj BLENNOW (Molndal); Merce BOADA (Barcelona); Maria CARRILLO (Chicago); Mony John DE LEON (New York); Steven DEKOSKY (Gainesville); Rachele DOODY (Basel); Bruno DUBOIS (Paris); Howard FELDMAN (San Diego); Nick FOX (London); Giovanni B. FRISONI (Brescia, Geneva); Lutz FROELICH (Mannheim); Serge GAUTHIER (Montreal); Ezio GIACOBINI (Geneva); Michael GRUNDMANN (San Diego); Harald HAMPEL (Woodcliff Lake); Takeshi IWATSUBO (Tokyo); Ara KHACHATURIAN (Washington DC); Zaven KHACHATURIAN (Washington DC); Virginia LEE (Philadelphia); Constantine G. LYKETSOS (Baltimore); José Luis MOLINUEVO (Barcelona); Jean-Marc ORGOGOZO (Bordeaux); Ronald PETERSEN (Rochester); Craig W. RITCHIE (Edinburgh); Augustin RUIZ (Barcelona); Robert RISSMAN (San Diego); Marwan SABBAGH (Las Vegas); Stephen SALLOWAY (Providence); Rachel SCHINDLER (New York); Philip SCHELTENS (Amsterdam); Lon SCHNEIDER (Los Angeles); Eric SIEMERS (Philadelphia); Peter SNYDER (Rhode Island); Reisa SPERLING (Boston); Yaakov STERN (New York); Jacques TOUCHON (Montpellier); John TROJANOWSKI (Philadelphia); Bruno VELLAS (Toulouse); Michael W. WEINER (San Francisco); Bengt WINBLAD (Stockholm)

# ● Wednesday, DECEMBER 4

- 4.00 p.m. **Opening Ceremony and CTAD Lifetime Achievement Award**  
Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner
- 4.30 p.m. **KEYNOTE 1**  
**How to interpret recent failures for the Beta-Amyloid target?**  
Stephen Salloway, MD, MS - Chief of Neurology and Director of the Memory and Aging Program, Butler Hospital, Providence, RI, USA
- 5.00 p.m. **SYMPOSIUM 1**  
**New Results on the Relationship between Intensive Blood Pressure Control and Cognitive Function from SPRINT-MIND**  
Chair: Kristine Yaffe, University of California at San Francisco (UCSF), San Francisco, CA, USA
- PRESENTATION 1: Effect of intensive blood pressure control on subtypes of mild cognitive impairment**  
Sarah Gaussoin, Wake Forest School of Medicine, Winston-Salem, NC, USA
- PRESENTATION 2: Lessons Learned from Cognitive Outcomes in SPRINT: Neuropsychological Test Scores, Domain-Specific Cognitive Function, and Adjudicated Outcomes**  
Nicholas M. Pajewski, Wake Forest School of Medicine, Winston-Salem, NC, USA
- PRESENTATION 3: Effect of intensive blood pressure control on brain MRI biomarkers**  
Ilya Nasrallah, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
- 6.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

# ● Thursday, DECEMBER 5

- 8.00 a.m. **LATE BREAKING ORAL COMMUNICATIONS**
- 9.00 a.m. **ORAL COMMUNICATIONS SESSION**
- 9.00 a.m. **OC1 - Comparative Effectiveness of behavioral interventions in Mild Cognitive Impairment: 12-month outcomes of a Randomized Clinical Trial**  
Glenn Smith, University of Florida, Gainesville, FL, USA
- 9.15 a.m. **OC2 - AADvac1 tau vaccine completing the phase 2 study: a paradigm shift for the AD treatment hypothesis**  
Matej Ondrus, AXON Neuroscience CRM Services SE, Bratislava, Slovakia

# ● Thursday, DECEMBER 5



9.30 a.m. **OC3 - Treatment with Donanemab, a  $\beta$ -amyloid plaque-specific antibody, results in rapid and sustained reduction of amyloid measured by F-18 florbetapir imaging in Alzheimer's disease**  
Stephen Lowe, Lilly Centre for Clinical Pharmacology, Singapore, Singapore

9.45 a.m. **OC4 - Automatic speech recognition can deliver large-scale, remote assessments of cognition**  
Francesca Cormack PhD (1,2), Merina Su PhD (1), Jennifer H. Barnett PhD (1,2), Nick Taptiklis (1)  
(1) Cambridge Cognition, Cambridge - UK, (2) University of Cambridge, Cambridge - UK

10.00 a.m.  Coffee Break and poster sessions

## 10.30 a.m. SYMPOSIUM 2

### New Predictive Platforms for Advancing Drug Combination Approaches for Alzheimer Pathology

Chairman: Lon Schneider, Keck School of Medicine of USC, Los Angeles, CA, USA

**PRESENTATION 1: In Silico Screening of Medications for Slowing Alzheimer's Disease Progression in a Clinical Trials Meta-database**  
Richard E. Kennedy, University of Alabama, Birmingham, AL, USA

**PRESENTATION 2: Drug Combination Identification through Correlation between a Clinical Dataset and a Computational Model**  
Thomas J. Anastasio, University of Illinois at Urbana-Champaign, Urbana, IL, USA

**PRESENTATION 3: Evaluating Pharmacodynamic Interactions in Drug Combinations Using Quantitative Systems Pharmacology Analysis of Clinical Trials**  
Hugo Geerts, In Silico Biosciences, Berwyn, PA, USA

## 11.30 a.m. ORAL COMMUNICATIONS SESSION

11.30 a.m. **OC5 - Development of cognitive go/no-go decision-making criteria in early clinical development of agents to treat Alzheimer's disease**

Alette Wessels, PhD (1), Chris J. Edgar PhD (2), Gregory Light, PhD (3), Pradeep Nathan, PhD (4), Eric Siemers, MD (5), Paul Maruff, PhD (6), John Harrison, PhD (7)

(1) Eli Lilly and Company, Indianapolis, IN, USA, (2) Cogstate Ltd, London, UK, (3) Department of Psychiatry, University of California, San Diego, USA, (4) SoseiHeptares, Cambridge, UK; Department of Psychiatry, University of Cambridge UK; School of Psychological Sciences, Monash University, Australia, (5) Cogstate Ltd, New Haven, CT, USA, (6) Cogstate Ltd., Melbourne, Australia, (7) Metis Cognition Ltd, Kilmington Common, UK; Alzheimer Center AUmc, Amsterdam, The Netherlands; Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK

11.45 a.m. **OC6 - Efficacy and safety results of REVERSE-SD, phase-2b clinical study of the selective p38 $\alpha$  kinase inhibitor neflamapimod in early-stage Alzheimer's disease (AD)**

Philip Scheltens, Alzheimer Center, Amsterdam UMC, Amsterdam, The Netherlands

12.00 p.m. **OC7 - Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimer's disease (CREAD/CREAD2): Biomarker results**

Tobias Bittner, F. Hoffmann-La Roche Ltd, Basel, Switzerland

12.15 p.m. **OC8 - DHA Brain Delivery Pilot Study: A randomized clinical trial**

Hussein Yassine, USC, Los Angeles, CA, USA

12.30 p.m.  Lunch and Poster Sessions

## 1.30 p.m. KEYNOTE 2

### Overview of the NIA portfolio in AD clinical trials: Which new targets could be explored?

Eliezer Masliah, MD - Director of the Division of Neuroscience, National Institute on Aging (NIA), Bethesda, USA

# ● Thursday, DECEMBER 5

2.00 p.m

## ROUNDTABLE

### Pros and Cons of Weighted Composite Scores for Preclinical and Prodromal Alzheimer's Disease

Moderators: Sandrine Andrieu MD, PhD, Inserm, University of Toulouse, Toulouse, France, Pierre Tariot MD, Banner Alzheimer Institute, Phoenix, AZ, USA

#### PRESENTATION 1: Important Considerations for Statistically Deriving Weighted Composite Scores for Alzheimer's Disease

Suzanne Hendrix, Pentara Corp, Salt Lake City, UT, USA

#### PRESENTATION 2: The Weighting Game: What Impact Do Weights Have on Composite Scores - Are They Worth It?

Kun Jin, Statistical Team Leader, US Food and Drug Administration, Washington, DC, USA

3.30 p.m



Coffee Break and poster sessions

4.00 p.m

## SYMPOSIUM 3

### Epigenetics and the BET-system in vascular dementia, Alzheimer's disease and mixed dementia – the problem and potential remedies

Chairman: Bengt Winblad, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

#### PRESENTER 1: Dementias, who and how to treat and by what specialty . Addressing problem and current and potential future therapeutic practices

Charles DeCarli, MD, FAAN, FAHA, UC Davis, CA, USA

#### PRESENTER 2: Fluid biomarkers that predict and project brain health

Henrik Zetterberg, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

#### PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease

Ewelina Kulikowski, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

#### PRESENTER 4: Epigenetics, the BET-system, Alzheimer's Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease

Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

5.00 p.m

## LATE BREAKING ORAL COMMUNICATIONS

● Friday,  
**DECEMBER 6**



8.00 a.m. **LATE BREAKING ORAL COMMUNICATIONS**

9.00 a.m. **ORAL COMMUNICATIONS SESSION**

9.00 a.m. **OC9 - Anchor- and Distribution-based methods to establish clinically meaningful score changes on the Clinical Dementia Rating Scale – Sum of Boxes in patients with prodromal Alzheimer’s Disease**

*Claire Lansdall, Roche Products Limited, Welwyn Garden City, UK*

9.15 a.m. **OC10 - Awareness of Genetic Risk in the Dominantly Inherited Alzheimer Network (DIAN)**

*Jason Hassenstab, Washington University in St. Louis, MO, USA*

9.30 a.m. **OC11 - Umibecestat: a BACE1 inhibitor continuing to assess potential for AD prevention in the Generation Program**

*Ana Graf, Novartis Pharma, Basel, Switzerland*

9.45 a.m. **OC12 - Recruitment Strategies for the Generation Program AD Prevention Clinical Trials: Lessons from the Butler Hospital Memory & Aging Program**

*Jessica Alber, University of Rhode Island, Kingston, RI, USA*

10.00 a.m.  Coffee Break and poster sessions

10.30 a.m. **KEYNOTE 3**

**Failure after failure, what’s next in AD Drug Development?**

*Paul Aisen, MD - Director of the Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, USC, San Diego, CA, USA*

11.00 a.m. **SYMPOSIUM 4**

**AMBAR (Alzheimer’s Management By Albumin Replacement) Phase 2B/3 Trial: complete clinical, biomarker and neuroimaging results**

*Chairman: Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA*

**PRESENTER 1:**

*Antonio Páez, Grifols, Barcelona, Spain*

12.00 p.m.  Lunch and poster sessions

1.00 p.m. **ORAL COMMUNICATIONS SESSION**

1.00 p.m. **OC13 - Thirty-six-month amyloid PET results show continued reduction in amyloid burden with gantenerumab**

*Gregory Klein, Roche Pharma Research and Early Development, Basel, Switzerland*

1.15 p.m. **OC14 - A Phase 1 Study of ALO02 in Healthy Volunteers and Patients With Mild-To-Moderate Alzheimer’s Disease**

*Robert Paul, Alector, Inc., South San Francisco, CA, USA*

1.30 p.m. **OC15 - Predicting sporadic Alzheimer’s progression via inherited Alzheimer’s-informed machine learning**

*Nicolai Franzmeier, Ludwig Maximilians University, Institute for Stroke and Dementia Research, Munich, Germany*

# ● Friday, DECEMBER 6

## ORAL COMMUNICATIONS SESSION

- 1.45 p.m. **OC16 - Continuously Acquired, Home-Based Digital Biomarkers of Activity and Function Are Related to Alzheimer's Disease Neuropathology**  
*Jeffrey Kaye, Oregon Health & Science University, Portland, OR, USA*
- 2.00 p.m. **OC17 - The Alzheimer's Clinical Trials Consortium Seeks Partners for Therapeutic Trials**  
*Sarah Walter, Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California, San Diego, USA*
- 2.15 p.m. **OC18 - The EXERT Trial: Testing a Model for Effective Community-Based Exercise Intervention Delivery for Adults with MCI**  
*Jeffrey Katula, Wake Forest School of Medicine, Winston-Salem, NC, USA*
- 2.30 p.m. **OC19 - The effects of rasagiline upon cerebral glucose metabolism, cognition, and tau in patients with mild to moderate Alzheimer's disease: Results of a Phase II clinical trial**  
*Dawn Matthews, ADM Diagnostics Inc, Northbrook, IL, USA*
- 2.45 p.m. **OC20 - Towards a florbetapir-based dual -biomarker screening strategy**  
*Sergey Shcherbinin, Eli Lilly & Company, Indianapolis, IN, USA*
- 3.00 p.m. **KEYNOTE 4**  
**Next generation of multidomain lifestyle clinical trials: Design and implementation for proof of scientific concept and pragmatic sustainability**  
*Laura D. Baker, PhD - Associate Professor, Gerontology and Geriatric Medicine, Wake Forest School Medicine, Winston-Salem, NC, USA*
- 3.30 p.m.  Coffee Break and poster sessions
- 4.00 p.m. **OC21 - FCSRT inclusion criteria support recruitment of a population with early Alzheimer's disease likely to progress over 24 months: results from the CREAD trial**  
*Kaycee Sink, Genentech, Inc., South San Francisco, CA, USA*
- 4.15 p.m. **OC22 - Assessing in Power in Phase II Proof-of-Concept Trials in Prodromal Alzheimer's Disease**  
*Michelle Nuno, Department of Statistics, University of California, Irvine, CA, USA*
- 4.30 p.m. **OC23 - The Alzheimer's disease THERapy with NEuroaid (ATHENE) Study: Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer's disease stable on Cholinesterase inhibitors or Memantine: A Randomized, double blind, placebo-controlled trial: BASELINE RESULTS**  
*Christopher Chen, National University of Singapore, Singapore*
- 4.45 p.m. **OC24 - Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients**  
*Xue Hua, Athira Pharma, Inc, Seattle, WA, USA*
- 5.00 p.m. **LATE BREAKING ORAL COMMUNICATIONS**



# ● Saturday, DECEMBER 7



8.00 a.m LATE BREAKING ORAL COMMUNICATIONS

9.00 a.m **ROUNDTABLE**

**Sex/gender consideration in clinical trials and potential improvements to clinical trial design**

Merce Boada (1,2,3), Antonella Santuccione, (4,7), Maria Teresa Ferretti MT (4,5,6), Cassandra Szoeki (8), Jennifer Ann Zimmer (9)

(1) Research Center and Memory Clinic. Fundació ACE, Institut Català de Neurociències Aplicades, (2) Universitat Internacional de Catalunya- Barcelona, Spain, (3) Networking Research Center on Neurodegenerative Disease (CIBERNED), Instituto de Salud Carlos III, Spain, (4) Women's Brain Project, Guntershausen, Switzerland, (5) Institute for Regenerative Medicine-IREM, University of Zurich, Zurich, Switzerland, (6) Neuroscience Center Zurich (ZNZ), University of Zurich, Zurich, Switzerland, (7) Global Medical and Scientific Affairs, Roche Diagnostics International Ltd., Rotkreuz, Switzerland, (8) Women's Healthy Ageing Project, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia, (9) Eli Lilly and Company, Indianapolis, IN, USA

9.30 a.m

**KEYNOTE 5 (to be confirmed)**

**Digital Clinical Trials: It's Not (all) About the Tech!**

**Amy P. Abernethy, M.D., Ph.D - Principal Deputy Commissioner of Food and Drugs, USA**

10.00 a.m



Coffee Break and poster sessions

10.30 a.m

**ORAL COMMUNICATIONS SESSION**

10.30 a.m

**OC25 - Regulation of glial cell activation and neurodegeneration by anti-semaphorin 4D antibody pepinemab (VX15/2503), a potential treatment for Alzheimer's and Huntington's Disease**

Elizabeth Evans, Vaccinex, Rochester, NY, USA

10.45 a.m

**OC26 - Therapeutic ultrasound as a treatment strategy for Alzheimer's disease - preclinical data (including Aducanumab) and clinical trial design**

Jürgen Götz, The University of Queensland, Queensland Brain Institute, Brisbane, Australia

11.00 a.m

**OC27 - Baseline Clinical and Biomarker Characteristics from a Phase 2 Trial of R07105705 in Prodromal-to-Mild Alzheimer's Disease (Tauriel)**

Edmond Teng, Genentech, South San Francisco, CA, USA

11.15 a.m

**OC28 - COR388, A Novel Gingipain Inhibitor, Decreases Fragmentation of ApoE in Alzheimer's Disease Central Nervous System**

Michael Detke, Cortexyme, South San Francisco, CA, USA

11.30 a.m

**SYMPOSIUM 5**

**Alzheimer's Disease in Down Syndrome: New Insights and Opportunities**

Chairman : Michael Rafii, USC, San Diego, CA, USA

**PRESENTATION 1: Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome**

Andre Strydom, King's College London, London, UK

**PRESENTATION 2: Neuroimaging biomarkers of AD in DS**

Brad Christian, University of Wisconsin, Madison, WI, USA

**PRESENTATION 3: Plasma and CSF biomarkers for the diagnosis of AD in DS**

Juan Fortea, Hospital Saint Pau, Barcelona, Spain

# ● Saturday, DECEMBER 7

12.30 p.m.  Lunch and Poster Sessions

## ORAL COMMUNICATIONS SESSION

- 1.30 p.m. **OC29 - Binding profiles of BAN2401 and aducanumab to different amyloid-beta species**  
*Lars Lannfelt, Uppsala University, Uppsala, Sweden*
- 1.45 p.m. **OC30 - Non-GLP Toxicity and Toxicokinetics Studies of P8, a Peptide Drug Candidate for the treatment of Alzheimer's Disease**  
*Nanzeen Dewji, Cenna Biosciences Inc., La Jolla, CA, USA*
- 2.00 p.m. **OC31 - An exploratory examination of NeuroToolKit biomarkers across AD stages**  
*Carol Van Hulle, University of Wisconsin-Madison, Madison, WI, USA*
- 2.15 p.m. **OC32 - Improving Polygenic Risk Scores for Alzheimer's Disease**  
*Samuel Dickson, Pentara Corp., Salt Lake City, UT, USA*
- 2.30 p.m. **OC33 - Evaluating mixed effects models for burst cognitive data in Alzheimer disease clinical trials**  
*Guoqiao Wang, Washington University School of Medicine, St. Louis, MO, USA*
- 2.45 p.m. **OC34 - Safety, pharmacokinetics and pharmacodynamics of RDN-929: a potent and selective HDAC-CoREST complex inhibitor for the treatment of synaptopathies**  
*J. Michael Ryan, Rodin Therapeutics, Cambridge, MA, USA*
- 3.00 p.m. **OC35 - A Phase 2 trial of GRF6019 in mild-to-moderate Alzheimer's disease**  
*Jonas Hannestad, Alkahest, San Carlos, CA, USA*
- 3.15 p.m. **OC36 - HOPE4MCI Trial: Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer's Disease with AGB101**  
*Sharon Rosenzweig-Lipson, AgeneBio, Inc, Baltimore, MD, USA*
- 3.30 p.m. **OC37 - A review of volumetric MRI changes in AD treatment trials and a framework for their interpretation**  
*Adam Schwarz, Takeda, Cambridge, MA, USA*

3.45 p.m. **LATE BREAKING ORAL COMMUNICATIONS**

4.30 p.m. End of conference

# Registration



## Early bird fees (until September 17)

Early bird registration (no lunches) - 995 €

Early bird registration (3 lunches) - 1124 €

## Regular registration (from September 18)

Full registration (no lunches) - 1287 €

Full registration (3 lunches) - 1416 €

**Pack of 3 lunches** - 135 €

Please note that **REGISTRATION TO CTAD 2019 INCLUDES:** access to all CTAD sessions, CTAD 2019 abstracts, one-year online subscription to the Journal of Prevention of Alzheimer's Disease (JPAD) and conference materials.

You can register directly on our website [www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)


## Book your accommodation at the Conference Venue

This year again CTAD has negotiated a special price to stay at the **Hilton San Diego Bayfront** where CTAD will be held.

Hilton San Diego Bayfront  
1 Park Boulevard  
San Diego  
California, 92101

Book your room on our website  
[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

# Accommodations





© Sean Pavone/Photo

# CTAD Alzheimer 2019

Clinical Trials on Alzheimer's Disease

## Keep in touch

### SAN DIEGO 2019

CTAD Congress

Email: [ctad@ant-congres.com](mailto:ctad@ant-congres.com)

[www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)

### Follow us on



@CTADConference



CTAD Conference



CTAD Alzheimer

### #CTAD2019

## [www.ctad-alzheimer.com](http://www.ctad-alzheimer.com)